DOCSLIB.ORG

AMPI2019-11Print-1UP 1..95

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
AMPI2019-11Print-1UP 1..95 GENITOURINARY (NONPROSTATE) CANCER 4500 Oral Abstract Session, Mon, 8:00 AM-11:00 AM Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. Brian I. Rini, Elizabeth R. Plimack, Viktor Stus, Rustem Gafanov, Robert Hawkins, Dmitry Nosov, Frederic Pouliot, Denis Soulieres, Bohuslav Melichar, Ihor Vynnychenko, Sergio Jobim Azevedo, Delphine Borchiellini, Raymond S. McDermott, Jens Bedke, Satoshi Tamada, Shuyan Wan, Rodolfo F. Perini, Mei Chen, Michael B. Atkins, Thomas Powles; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Fox Chase Cancer Center, Philadelphia, PA; Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine, Dnipro, Ukraine; Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation; The Christie NHS Foundation Trust, Manchester, United Kingdom; Central Clinical Hospital with Outpatient Clinic, Moscow, Russian Federation; CHU de Quebec ´ and Universite ´ Laval, Quebec City, QC, Canada; Centre Hospitalier de l’Universite ´ de Montreal, ´ Montreal, QC, Canada; Palacky ´ University Medical School and Teaching Hospital, Olomouc, Czech Republic; Sumy State University, Sumy Regional Oncology Center, Sumy, Ukraine; Hospital de Clı´nicas de Porto Alegre, Porto Alegre, Brazil; Centre Antoine Lacassagne, UniversiteC ´ oteˆ d’Azu, Nice, France; Adelaide and Meath Hospital and University College Dublin, Dublin, Ireland; Department of Urology, Eberhard- Karls University Tubingen, ¨ Tubingen, ¨ Germany; Osaka City University Hospital, Osaka, Japan; Merck & Co., Inc., Kenilworth, NJ; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Barts Health and the Royal Free NHS Trusts, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom Background: In KEYNOTE-426, pembro + axi significantly improved OS (HR 0.53, P , .0001), PFS (HR 0.69, P = .0001), and ORR (59.3% vs 35.7%, P , .0001) vs sunitinib and had manageable toxicity as first-line therapy for mRCC (NCT02853331). The pembro + axi benefit was observed across all IMDC risk groups and regardless of PD-L1 expression. We present data for the combined intermediate/poor risk group and for patients (pts) with sarcomatoid features. Methods: 861 eligible pts with clear-cell mRCC, no prior systemic therapy for mRCC, and KPS $70 were randomized 1:1 to pembro 200 mg IV Q3W for a maximum of 35 cycles plus axi 5 mg orally BID (N = 432) or sunitinib 50 mg orally QD (4-wk on/2-wk off) (N = 429). Primary endpoints were OS and PFS (RECIST v1.1 by blinded, independent central review [BICR]). ORR (RECIST v1.1 by BICR) was the key secondary endpoint. The intermediate/poor risk group was prespecified; the sarcomatoid group was exploratory. HRs and their 95% CIs were calculated with a Cox proportional hazards model. None of the analyses were multiplicity-controlled. Results: 592 (68.8%) of all randomized pts were of IMDC intermediate/poor risk — 294 in the pembro + axi arm, 298 in the sunitinib arm. Pembro + axi improved OS (HR 0.52, 95% CI 0.37-0.74; 12-mo rate 87.3% vs 71.3%), PFS (HR 0.67, 95% CI 0.53-0.85; median 12.6 vs 8.2 mo), and ORR (55.8% [95% CI 49.9-61.5] vs 29.5% [24.4-35.1]) in pts with intermediate/poor risk; CR rates were 4.8% (95% CI 2.6-7.9) vs 0.7% (0.1-2.4). Of the 578 pts with known status, 105 (18.2%) had sarcomatoid features — 51inthepembro+ axi arm, 54 in the sunitinib arm. Pembro + axi improved OS (HR 0.58, 95% CI 0.21-1.59; 12-mo rate 83.4% vs 79.5%), PFS (HR 0.54, 95% CI 0.29-1.00; mediannotreachedvs8.4mo),andORR(58.8% [95% CI 44.2-72.4] vs 31.5% [19.5-45.6]) in pts with sarcomatoid features; CR rates were 11.8% (95% CI 4.4-23.9) vs 0% (0.0-6.6). Conclusions: Pembro + axi provides benefit in the combined population of pts with IMDC intermediate or poor risk and in pts whose tumors had sarcomatoid features. The observed benefits were consistent with those seen in the total population. Clinical trial information: NCT02853331. © 2019 American Society of Clinical Oncology. Visit abstracts.asco.org and search by abstract for disclosure information. GENITOURINARY (NONPROSTATE) CANCER 4501 Oral Abstract Session, Mon, 8:00 AM-11:00 AM A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx). Jianjun Gao, Jose A. Karam, Nizar M. Tannir, Matthew T Campbell, Rebecca Slack Tidwell, Kamran Ahrar, Priya Rao, Chaan S. Ng, Eric Jonasch, Surena F. Matin, Amado J. Zurita, Amishi Yogesh Shah, Yu Shen, Jorge M. Blando, Luis M. Vence, Sreyashi Basu, Hao Zhao, James Patrick Allison, Christopher G. Wood, Padmanee Sharma; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX Background: Cytoreductive surgery (CS) including cytoreductive nephrectomy and metastasectomy pro- vides clinical benefits to patients with MRCC. However, CS has not been evaluated in the setting of immune checkpoint (IC) therapy. We performed a pre-surgical/biopsy trial to evaluate biological and clinical activity of nivo +/- (bev or ipi) in patients with MRCC. Methods: In this open-label, randomized trial (NCT02210117), patients with MRCC w/o prior IC therapy and anti-VEGF therapy were randomized 2:3:2 to receive nivo (3mg/kg q2wks x3), nivo + bev (10mg/kg q2wks x3) or nivo + ipi (1mg/kg q3wks x2), followed by CS or Bx, and then nivo maintenance therapy up to 2 yrs. Clinical response per RECIST criteria was assessed at $12 wks. Pre- and post-treatment blood and tumors were obtained for correlative studies. Results: All of 105 patients have been accrued and 104 are evaluable for response. For all patients, best overall response (BOR = complete response [CR] + partial response [PR]) including surgery effect was 55% nivo, 44% nivo + bev, 43% nivo + ipi. Median PFS (95% confidence interval) was 14.5 months (5.5, not reached [NR]) nivo, 7.6 (4.8, 8.9) months nivo + bev, 7.5 (2.0, 12.4) months nivo + ipi. Overall survival (OS) at one year was 86% nivo, 73% nivo + bev, 83% nivo + ipi. Grade 3 or higher toxicities related to therapy were 38% for nivo, 42% for nivo + bev (including 18% hypertension), and 47% for nivo + ipi. For patients with CS, BOR including surgery effect was: 86% nivo, 88% nivo + bev, and 69% nivo + ipi. Median PFS was 17.3 months (6.1, NR) nivo, 7.6 (5.7, 10.3) months nivo + bev, 8.9 (2.9, 23.0) months nivo + ipi. OS at one year was 100% nivo, 94% nivo + bev, 92% nivo + ipi. Median OS has not yet reached with a median follow-up of 24.6 months. Immune and gene profiling analyses demonstrate: 1) tumor infiltrating CD8 T cells correlate with clinical responses to nivo or nivo + bev, but not to nivo + ipi; 2) tumor IFN pathway gene expression correlates with responses; and 3) PD-L1 status, tumor mutation or mutation burden, neoantigens did not correlate with response. Conclusions: ICtherapyplusCSissafeandbeneficial to patients with MRCC and therefore, warrants testing, along with a few correlative biomarkers, in a larger phase 3 trial. Clinical trial information: NCT 02210117. © 2019 American Society of Clinical Oncology. Visit abstracts.asco.org and search by abstract for disclosure information. GENITOURINARY (NONPROSTATE) CANCER 4502 Oral Abstract Session, Mon, 8:00 AM-11:00 AM Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following meta- stasectomy: A trial of the ECOG-ACRIN cancer research group (E2810). Leonard Joseph Appleman, Maneka Puligandla, Sumanta K. Pal, Wayne Harris, Neeraj Agarwal, Brian Addis Costello, Christopher W. Ryan, Michael Pins, Jill Kolesar, Daniel A. Vaena, Rahul Atul Parikh, Mehmood Hashmi, Janice P. Dutcher, Robert S. DiPaola, Naomi B. Haas, Michael Anthony Carducci; UPMC Hillman Cancer Center, Pittsburgh, PA; Dana-Farber Cancer Institute, Boston, MA; City of Hope National Medical Center, Duarte, CA; Emory University School of Medicine, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Mayo Clinic, Rochester, MN; Oregon Health & Science University, Knight Cancer Institute, Portland, OR; University of Illinois College of Medicine, Chicago, IL; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA; University of Kansas Cancer Center, Westwood, KS; University of Kansas, Kansas City, KS; Cancer Research Foundation of NY, Bronx, NY; University of Kentucky, Lexington, KY; Penn Medicine Abramson Cancer Center, Philadelphia, PA; Sidney Kimmel Cancer Center At Johns Hopkins, Baltimore, MD Background: Patients with no evidence of disease (NED) after metastasectomy for metastatic renal cell carcinoma (mRCC) are at high risk of recurrence, but no systemic therapy has been shown to benefit this population. Pazopanib is an inhibitor of VEGFR and other kinases that improves progression-free survival in patients with measurable RCC metastatic disease. We performed a randomized, double-blind, placebo- controlled multicenter study to test the hypothesis that pazopanib would improve disease-free survival in patients with mRCC rendered NED after metastasectomy Methods: Patients with NED following meta- stasectomy were randomized 1:1 to receive pazopanib starting at 800 mg daily vs. placebo for 52 weeks. Patients were stratified by 1 vs. 1 site of resected disease, and by disease-free interval # vs. 1year. Clinical assessment for toxicity and patient-reported outcomes were performed every 4 weeks, and restaging scans every 12 weeks.
Load more

Recommended publications
  • Across the Universe? a Comparative Analysis of Violent Behavior And
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Across the Universe? A Comparative Analysis of Violent Behavior and Radicalization Across Three Offender Types with Implications for Criminal Justice Training and Education Author(s): John G. Horgan, Ph.D., Paul Gill, Ph.D., Noemie Bouhana, Ph.D., James Silver, J.D., Ph.D., Emily Corner, MSc. Document No.: 249937 Date Received: June 2016 Award Number: 2013-ZA-BX-0002 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this federally funded grant report available electronically. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Across the Universe? A Comparative Analysis of Violent Behavior and Radicalization Across Three Offender Types with Implications for Criminal Justice Training and Education Final Report John G. Horgan, PhD Georgia State University Paul Gill, PhD University College, London Noemie Bouhana, PhD University College, London James Silver, JD, PhD Worcester State University Emily Corner, MSc University College, London This project was supported by Award No. 2013-ZA-BX-0002, awarded by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice. The opinions, findings, and conclusions or recommendations expressed in this publication are those of the authors and do not necessarily reflect those of the Department of Justice 1 ABOUT THE REPORT ABOUT THE PROJECT The content of this report was produced by John Horgan (Principal Investigator (PI)), Paul Gill (Co-PI), James Silver (Project Manager), Noemie Bouhana (Co- Investigator), and Emily Corner (Research Assistant).
    [Show full text]
  • Kountze Genealogy
    Descendants of Christian Gotlieb Kountze Generation No. 1 1. CHRISTIAN GOTLIEB1 KOUNTZE (JOHANN MICHELA KUNZE, JOHANN MICHAELB KUNZ) was born 04 Apr 1795 in Burkersdorf, Saxony, Germany, and died 24 Jan 1866 in Osnaburg, Stark County, OH. He married MARGARET ZERBE 24 Jan 1826 in Osnaburg, Stark County, OH, daughter of JOHN (ZERBE) and BARBARA SCHAEFFER. She was born 23 Feb 1807 in Near Greensburg, Western Orchard County, PA, and died 23 Feb 1887 in Hazelwood, near Pittsburgh, Allegheny Co., PA. More About CHRISTIAN KOUNTZE and MARGARET ZERBE: Marriage: 24 Jan 1826, Osnaburg, Stark County, OH Children of CHRISTIAN KOUNTZE and MARGARET ZERBE are: i. AUGUSTUS2 KOUNTZE, b. 19 Nov 1826, Osnaburg, Stark County, OH; d. 30 Apr 1892, New York, NY; m. CATHERINE RUTH, 14 Jun 1849; b. 1826, Hanoverton, Ohio. More About AUGUSTUS KOUNTZE and CATHERINE RUTH: Marriage: 14 Jun 1849 ii. MATILDA KOUNTZE, b. 22 Apr 1828, Osnaburg, Stark County, OH; m. (1) SAMUEL PHILLIP, 11 Sep 1845; m. (2) JAMES GARDINER, 10 Mar 1859. More About SAMUEL PHILLIP and MATILDA KOUNTZE: Marriage: 11 Sep 1845 More About JAMES GARDINER and MATILDA KOUNTZE: Marriage: 10 Mar 1859 2. iii. ADALINE KOUNTZE, b. 23 Jul 1830, Osnaburg, Stark County, OH. iv. ADOLPHUS CHRISTIAN KOUNTZE, b. 04 Aug 1832, Osnaburg, Stark County, OH; d. 23 Aug 1832, Osnaburg, Stark County, OH. 3. v. HERMAN KOUNTZE, b. 21 Aug 1833, Osnaburg, Stark County, OH; d. 20 Nov 1906, Omaha, NE. vi. WILLIAM KOUNTZE, b. 11 Apr 1836, Osnaburg, Stark County, OH; d. 06 Sep 1858, Dakota City, SD. 4. vii.
    [Show full text]
  • Heavyweight Cruiserweight Light Heavyweight
    WBA RATINGS COMMITTEE MARCH 2013 MOVEMENTS REPORT Based on results held from 03st March to 31th, 2013 Miguel Prado Sanchez Chairman Gustavo Padilla Vice Chairman HEAVYWEIGHT DATE PLACE BOXER A RESULT BOXER B TITLE REMARKS 03-08-2013 Atlantic city, New Jersey Magomed Abdusalamov KOT5 Victor Bisbal USNBC-WBC 03-23-2013 Berlin, Germany Ruslan Chagaev KO1 Mike Sheppard M. Brozio 60-54 P. Koslowski 59-56 03-23-2013 Czestochowa ,Poland Andrzej Wawrzyk UD 6 Robert Hawkins P. Moszumanski 60-54 MOVEMENT OUT Richard Towers out off to position # 13 by inactivity. (283 days) IN Malik Scott enters at position # 15 by caliber and activity # 14 Travis Kaufman goes up to position # 13 by automatic movement PROMOTIONS # 15 Mark De Mori goes up to position # 14 by automatic movement DEMOTIONS CRUISERWEIGHT DATE PLACE BOXER A RESULT BOXER B TITLE REMARKS MOVEMENT OUT NOT CHANGES IN NOT CHANGES PROMOTIONS NOT CHANGES DEMOTIONS NOT CHANGES LIGHT HEAVYWEIGHT 1 DATE PLACE BOXER A RESULT BOXER B TITLE REMARKS A. Van vangrootenbruel 115-113 Y.Koptev 115-113 03-16-2013 Kiev,Ukranie Doudov Ngumbu UD 12 Vyacheslav Uzelkov N.Monnet 116-113 03-22-2013 Quebec,Canada Eleider Alvarez KOT 3 Nocholson Poulard NABA,NABO M0VEMENT Vyacheslav Uzelkov out off to position # 4 by losing to a boxer unclassified as established by regulation OUT Nicholson Poulard out off to position # 6 by losing to a boxer unclassified as established by regulation Eleider Alvarez enters at position # 5 for winning a boxer classified and is a new champion NABA IN Doudou Ngumbu enters at position
    [Show full text]
  • Boston Medical Center VSGNE 2003 9 Member Hospitals
    Vascular Study Group of New England 16th Semi-Annual Meeting May 11, 2010 Boston Medical Center VSGNE 2003 9 Member Hospitals Fletcher Allen Health Eastern Maine Medical Center Care Cottage Hospital Central Maine Medical Center Dartmouth-Hitchcock Lakes Region Medical Center Hospital Maine Medical Center Concord Hospital Catholic Medical Center VSGNE 2011 27 Participating Hospitals 25 - 950 Hospital Beds Fletcher Allen Eastern Maine Medical Center Health Care Cottage Maine General Medical Center Hospital Central Maine Medical Center Dartmouth-Hitchcock Lakes Region Medical Center Hospital Maine Medical Center Rutland Regional Mercy Hospital Medical Center Concord Hospital Catholic Medical Center Elliot Hospital Berkshire Medical Center Tufts Medical Center Boston Medical Center U. Mass. Medical Center Beth Israel Deaconess Medical Center Baystate Medical Center Massachusetts General Hospital Brigham & Women’s Hospital Charlton Memorial Hospital St. Francis Hospital Caritas St. Anne’s Hospital Hartford Hospital St. Luke’s Hospital Yale-New Haven Hospital VSGNE 2011 27 Participating Hospitals 14 Community - 13 Academic Fletcher Allen Eastern Maine Medical Center Health Care Cottage Maine General Medical Center Hospital Central Maine Medical Center Dartmouth-Hitchcock Lakes Region Medical Center Hospital Maine Medical Center Rutland Regional Mercy Hospital Medical Center Concord Hospital Catholic Medical Center Elliot Hospital Berkshire Medical Center Tufts Medical Center Boston Medical Center U. Mass. Medical Center Beth Israel Deaconess Medical Center Baystate Medical Center Massachusetts General Hospital Brigham & Women’s Hospital Charlton Memorial Hospital St. Francis Hospital Caritas St. Anne’s Hospital Hartford Hospital St. Luke’s Hospital Yale-New Haven Hospital “Real World Practice” Maine New Hampshire Massachusetts Massachusetts Continued Connecticut Central Maine Medical Center, Lewiston Catholic Medical Center, Manchester Baystate Medical Center, Springfield Tufts Medical Center, Boston St.
    [Show full text]
  • Hardwick Will Iol Velvet Rugs
    SERMON BY BISHOP BRENT. ^ TTTTTTTTTTTTYi 4> MARRIEiD THIS AFTERr^JOON. SHIRTS BLANKETS comer Stone of Episcopal Chapel to ' * Be Placed Tuesday Next. CURTAINS COLLARS 4 -[ The Rt. Rev. Charles "]Favors" and Henry Brent, Original % < | to CUFFS . r LINGERIE piscopal missionary bishop the PhU- } ' V I pi nee. who »as twice electe<l aucceaaor the the late Bishop Sattcrlee as Bishop of 2 "Stouts" to Intensify $ I 'ashlngton. ami declined, will preach *» ie sermon at the laying of the corner one of the Bethlehem Chapel of the * olv Nativity next Tuesday afternoon i Fumi am Interest 11 The services will begin at .1 o'clock, TJ i VnBpiB^j^^l^^^^aE Ksi^B.1 11 yii itli Bishop Harding presiding and f « in the stone. Canons De Vrles and Bra-larg ^ o nahl are in charge of the arrangements. I.itt'.c Henry Y. tsatterlee, grandson of in the isliop batterlee, » 11) be present and as- j ± Bnnoimcement. st in the ceremonies of tin- A II U day. | rgo vested choir ami a se ti<>n of the \ arine Band will al>o participate The stone will be laid in the crypt of * f W.CTIf!fIM ! ie cathedral, and directly beneath tha Mj&Jjjuly) iffl JyM] ii iyyiiiiiiiiiiiiiyu/D ^ de HA>iD laneel. -. SALES N LAUNDRY. ^ ^ 110-1\ Conn. r You will find it eas^ to your for an Formerly Ave.) w perfect plans I. C. A. Alumnae. ma ^ \i .%*4?:: -' l.ast the a.umnae of Jl interesting and original Halloween Fete after you've iikhkm../ ^h^^e^kxkb^mhhqb Moml*;.
    [Show full text]
  • ESMO 2014 Advanced Programme
    esmocongress.org ADVANCED PROGRAMME ESMO 2014 Madrid, Spain 26-30 SEPTEMBER 2014 IMPORTANT DEADLINES 07 May 2014 Abstract submission and travel grant applications 18 June 2014 Early registration Organiser 23 July 2014 Group registration, participant names to be given 20 August 2014 Late-breaking abstract submission 20 August 2014 Late registration BASIC SCIENCE AND TRANSLATIONAL RESEARCH Saturday, 27 September 2014 Monday, 29 September 2014 10:30/ PATIENT CASES 11:00/ SPECIAL SYMPOSIUM 11:30 Cancer evolution: What can we learn from N=1 12:30 Genomic instability from bench to bedside molecular studies? Chair: Sheila Singh, Hamilton, ON, Canada Co-Chairs: Michael Taylor, Toronto, ON, Canada and Tariq Enver, Co-Chair: Charles Swanton, London, UK London, UK Introduction Evolution of acute lymphoblastic leukemia (ALL) in identical twins Charles Swanton, London, UK Tariq Enver, London, UK The emerging role of HELQ in homologous recombination repair Clonal evolution of childhood cancers in ovarian cancer Michael Taylor, Toronto, ON, Canada Rebecca Burrell, London, UK Discussion Replication stress and DNA damage response in solid tumours Jiri Bartek, Copenhagen, Denmark The interface between cancer numerical and structural Sunday, 28 September 2014 chromosomal instability: Mechanisms accelerating cancer diversity 09:15/ JOINT SYMPOSIUM: ESMO - JSMO 10:45 How to implicate genome sequencing data in oncology René Medema, Amsterdam, Netherlands Co-Chairs: Jean-Yves Douillard, St. Herblain, France and Targeting cancer aneuploidy: Light at the end
    [Show full text]
  • 2018 Detailed Annual Report
    2018 Detailed Annual Report © Society for Vascular Surgery Patient Safety Organization, 2018. All rights reserved. TABLE OF CONTENTS 1. Executive Summary: The Value of Participation in the VQI 3 2. VQI Members Profile 5 3. Outcomes and Data Quality Dashboards 6 4. Regional Quality Groups 7 5. Quality Improvement Projects: Learning from the Data 8 6. VQI National QI Projects 9 7. VQI Data Analysis 12 8. Using VQI Data for Collaborative Projects 12 9. Future Developments 15 APPENDICES A. Participating Sites 17 B. SVS Patient Safety Organization 19 C. Medstreaming/M2S Technology Partner 19 D. VQI Registry Dashboards 20 E. Sample COPI Report (Endovascular AAA Length of Stay) and Best Practice Dashboard (Center-level) 32 F. VQI Regional Quality Groups and Leadership 37 G. VQI Quality Improvement Projects 2017/18 38 H. National Approved Project List, October 2017 – September 2018 39 I. National Publications, October 2017 – September 2018 44 J. SVS PSO Councils and Registry Committees 49 2 SVS VQI 2018 Annual Report 1. EXECUTIVE SUMMARY—THE VALUE OF PARTICIPATION IN THE VASCULAR QUALITY INITIATIVE (VQI) “If you can’t measure it, you can’t improve it.” This management catchphrase has been attributed to Edwards Deming, Peter Drucker, Lord Kelvin and others, but it could serve as the founding principle of the Vascular Quality Initiative. Our mission is to gath- er data to help hospitals and providers assess their performance and provide better vascular care. VQI’s 12 registries contain demographic, clinical, use the strength of different societies (VQI, NCDR, procedural and outcomes data from more and SIR) to enhance device evaluation and than 500,000 vascular procedures performed to develop objective performance criteria for nationwide and in Canada.
    [Show full text]
  • American Society of Clinical Oncology (ASCO) Annual Meeting 2019 Friday, May 31 – Tuesday, June 4
    American Society of Clinical Oncology (ASCO) Annual Meeting 2019 Friday, May 31 – Tuesday, June 4 https://am.asco.org/ Cancer Center Members indicated in BOLD Presentations and Session Chairs Mikkael A. Sekeres, MD, MS, Cleveland Clinic Taussig Cancer Institute Interactive Case-Based Session: Do We Know How to Use Hypomethylating Agents in Myeloid Disorders? Speaker, “What Is the Right Decitabine Treatment Duration?” Friday, May 31, 2019, 1:00 PM - 2:00 PM, E451 Nathan A. Pennell, MD, PhD, Cleveland Clinic Chair, Education Session: Real-World Tumor/Plasma Genetic Testing: Tough Choices, How Do You Pick? Speaker, “Guidelines, Barriers, Access to Molecular Testing in NSCLC” Friday, May 31, 2019, 2:45 PM - 3:00 PM, Hall D1 Pradnya Dinkar Patil, MD, FACP, Cleveland Clinic Education Session: On the Shoulders of Giants: Past, Present, and Future of Systemic Therapy for Lung Cancer Speaker, “The Next Frontier: Understanding and Overcoming Resistance to Targeted Therapy and Immunotherapy” Friday, May 31, 2:45 PM – 4:00 PM, S100bc Eric Kodish, MD, Cleveland Clinic Chair, Education Session: Obtaining Consent in Pediatric Oncology: New and Ongoing Challenges Speaker, “Ethical Care Practices: Respecting Cultural and Societal Differences to Safeguard the Therapeutic Relationship” Monday, June 3, 2019, 8:00 AM – 8:20 AM, S504 Jennifer S. Yu, MD, PhD, Cleveland Clinic Chair, Education Session: Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal? Speaker, “To Radiate or Not to Radiate: Nuances of Radiation Therapy for Low-Grade Gliomas” Monday, June 3, 2019, 10:00 AM – 10:15 AM, E451 Brian I. Rini, MD, FACP, Cleveland Clinic Taussig Cancer Institute Panelist, Interactive Case-Based Session: Emerging New Standards of Care for Advanced Kidney Cancer Monday, June 3, 2019, 11:30 AM – 12:30 PM, E451 Cancer Center members indicated in BOLD Alberto J.
    [Show full text]
  • ITOC4 Programme
    Presented by CDDF in collaboration with SITC: THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE 20 MARCH 22 2017 FINAL PROGRAMME PRAGUE CZECH REPUBLIC 5TH Immunotherapy Of Cancer Conference THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE cancer cell © vitanovski MARCH 19-21, 2018 BERLIN, GERMANY 5TH EDITION MARCH 19-21, 2018 BERLIN, GERMANY www.itoc-conference.eu SAVE THE DATE 4TH IMMUNOTHERAPY OF CANCER CONFERENCE TABLE OF CONTENTS WELCOME LETTER PAGE 4 CANCER DRUG DEVELOPMENT FORUM & PARTNERS PAGE 5 ORGANISING PARTNERS PAGE 5 CONFERENCE COMMITTEE PAGE 6 ACCREDITATION FOR CONTINUOUS MEDICAL EDUCATION (CME) PAGE 6 PROGRAMME AT A GLANCE PAGE 7 SCIENTIFIC PROGRAMME PAGE 8 POSTERS PAGE 10 FLOORPLAN PAGE 13 ACKNOWLEDGMENTS PAGE 14 EXHIBITORS PAGE 15 PARTNERS PAGE 16 GENERAL INFORMATION PAGE 17 CORPORATE SATELLITE SYMPOSIUM PAGE 21 FINAL PROGRAMME FINAL 3 4TH IMMUNOTHERAPY OF CANCER CONFERENCE WELCOME LETTER Welcome to the fourth edition of the Immunotherapy of Cancer conference (ITOC4), the premier meeting for education, scientific exchange and networking within cancer immunotherapy. This meeting has been growing rapidly into a global platform for translational research in the field of immuno-oncology. The scientific programme with an international faculty will focus on many topics such as Preclinical models, Micro-environment and Immune Regulation, Emerging concepts and novel targets, Combination therapy, Monitoring of immune response in the clinic, Therapeutic antibodies and Cell therapy. Organised by the Cancer Drug Development Forum (CDDF), whose mission is to provide a unique platform to facilitate interactions between all stakeholders (academia, regulatory authorities, policymakers, industry, patient advocacy groups and health technology assessors) to improve the efficiency of cancer drug development and in cooperation with Society for Immunotherapy of Cancer (SITC), the ITOC conference series aim to provide a forum for discussion of early clinical drug development and address its unique challenges.
    [Show full text]
  • Stage-Coach Days in the Bluegrass
    University of Kentucky UKnowledge United States History History 1995 Stage-Coach Days In The Bluegrass J. Winston Coleman Jr. Click here to let us know how access to this document benefits ou.y Thanks to the University of Kentucky Libraries and the University Press of Kentucky, this book is freely available to current faculty, students, and staff at the University of Kentucky. Find other University of Kentucky Books at uknowledge.uky.edu/upk. For more information, please contact UKnowledge at [email protected]. Recommended Citation Coleman, J. Winston Jr., "Stage-Coach Days In The Bluegrass" (1995). United States History. 104. https://uknowledge.uky.edu/upk_united_states_history/104 IN THE BLUEGRASS Being an Account ofStage-Coach Travel and Tavern Days in Lexington and Central Kentucky 1800-1900 J. WINSTON COLEMAN, JR. FOREWORD BY THOMAS D. CLARK THE UNIVERSITY PRESS OF KENTUCKY Publication of this volume was made possible in part by grants from The Thomas D. Clark Foundation, the Lexington-Fayette County Historic Commission, and the Lexington Historical Publishing Corporation. Copyright © 1935 by J. Winston Coleman, Jr. Originally published by the Standard Press, Louisville, Kentucky, 1935 Foreword copyright © 1995 by The University Press of Kentucky Scholarly publisher for the Commonwealth, serving Bellarminc College, Berea College, Centre College of Kentucky, Eastern Kentucky University, The Filson Club, Georgetown College, Kentucky Historical Society, Kentucky State University, Morehead State University, Murray State University, Northern Kentucky University, Transylvania University, University of Kentucky, University of Louisville, and Western Kentucky University. Editorial and Sales Offices: The University Press of Kentucky 663 South Limestone Street, Lexington, Kentucky 40508-4008 Library of Congress Catalog-in-Publication Data Coleman, J.
    [Show full text]
  • Wake Forest Vs Clemson (10/31/1981)
    Clemson University TigerPrints Football Programs Programs 1981 Wake Forest vs Clemson (10/31/1981) Clemson University Follow this and additional works at: https://tigerprints.clemson.edu/fball_prgms Materials in this collection may be protected by copyright law (Title 17, U.S. code). Use of these materials beyond the exceptions provided for in the Fair Use and Educational Use clauses of the U.S. Copyright Law may violate federal law. For additional rights information, please contact Kirstin O'Keefe (kokeefe [at] clemson [dot] edu) For additional information about the collections, please contact the Special Collections and Archives by phone at 864.656.3031 or via email at cuscl [at] clemson [dot] edu Recommended Citation University, Clemson, "Wake Forest vs Clemson (10/31/1981)" (1981). Football Programs. 153. https://tigerprints.clemson.edu/fball_prgms/153 This Book is brought to you for free and open access by the Programs at TigerPrints. It has been accepted for inclusion in Football Programs by an authorized administrator of TigerPrints. For more information, please contact [email protected]. CLEMSON MEMORIAL STADIUM $2.00 0* WAKE FOREST OCTOBER 31, 1981 Serving The Textile Finishing Industry LEADERS IN ENERGY CONSERVATION SUPPORTING m THE - ^$TIGERS SINCE 1920 Manufacturers of Quality Textile Finishing Machinery MARSHALL and WILLIAMS COMPANY 46 Baker St., Providence, R. i. 02905 620 South Pleasontburg Dr., Greenville, S. C. 29606 Area Code 401-461-3450 Area Code 803-242-6750 Contents Today's Features Departments October 31, 1981 Today's Game and Statistics Today's Matchups Clemson vs. Wake Forest Athletic Administration Clemson Memorial Stadium University Officials Cover Story C Stadium Information Jeff Bryant is one of the leaders of Clem- Athletic Dept.
    [Show full text]
  • Store Store Manager Address City State Zip Phone 1158 JEFFREY
    Store Store Manager Address City State Zip Phone 1158 JEFFREY JAY 2473 HACKWORTH RD ADAMSVILLE AL 35214 2057989721 423 JOSHUA BURCH 630 COLONIAL PROMENADE PKWY ALABASTER AL 35007 2056200360 4756 JONATHAN WEBB 9085 HWY 119 ALABASTER AL 35007 2056246229 726 ROGER PHILLIPS 2643 HIGHWAY 280 ALEXANDER CITY AL 35010 2562340316 1091 EARL ALSOBROOKS 1991 DR M L K JR EXPY ANDALUSIA AL 36420 3342226561 329 RICHARD HIGGINS 5560 MCCLELLAN BLVD ANNISTON AL 36206 2568203326 306 DAVID SIMS 1450 N BRINDLEE MOUN ARAB AL 35016 2565868168 661 LORI HUNTLEY 1011 US HIGHWAY 72 E ATHENS AL 35611 2562302981 7247 ERIN HANKINS 911 N MAIN STREET ATMORE AL 36502 2513681403 316 JOSHUA KIDD 973 GILBERT FERRY RD SE ATTALLA AL 35954 2565383811 356 KEITH MOCK 1717 S COLLEGE ST AUBURN AL 36832 3348212493 4673 CHRISTINA DENTON 1810 SHUG JORDAN PARKWAY AUBURN AL 36832 3345396318 5062 BRIAN GALLUPS 2047 E UNIVERSITY DR AUBURN AL 36830 3345396214 2739 VICTOR MORGAN III 701 MCMEANS AVE BAY MINETTE AL 36507 2519375558 764 RAYMOND DAVIDSON JR. 750 ACADEMY DR BESSEMER AL 35022 2054245890 762 CEDRICKIA TOWNS 9248 PARKWAY E BIRMINGHAM AL 35206 2058337676 1711 MICHAEL WATSON 1600 MONTCLAIR RD BIRMINGHAM AL 35210 2059560416 2111 RICHARD EDWARDS 5335 HIGHWAY 280 BIRMINGHAM AL 35242 2059805156 3424 JEREMY CROOK 2653 VALLEYDALE ROAD BIRMINGHAM AL 35244 2055826183 4504 ANTIONETTE WILLIAMS 312 PALISADES BLVD BIRMINGHAM AL 35209 2058708101 5100 TRACY SMELCER 1916 CENTER POINT PKWY BIRMINGHAM AL 35215 2055200269 298 JOSHUA CRANE 1972 HIGHWAY 431 BOAZ AL 35957 2565930195 425 CHARLES SANDERS
    [Show full text]